The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.9M data for 1.2M Compounds and 9.3K Targets. Of those, 1,352K data for 627K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

15 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Use of a dipeptide chemical library in the development of non-peptide tachykinin NK3 receptor selective antagonists.EBI
Cambridge University Forvie Site
A new class of high affinity ligands for the neurokinin A NK2 receptor: psi (CH2NR) reduced peptide bond analogues of neurokinin A4-10.EBI
Marion Merrell Dow Research Institute
 
Design and synthesis of a targeted set of aromatic amino acid derivatives for identification of new lead compoundsEBI
TBA
 
2,3-Substituted 2-azanorbornanes as polar -turn mimeticsEBI
TBA
 
The development of a novel series of non-peptide tachykinin NK3 receptor selective antagonistsEBI
TBA
 
The design of polar -turn dipeptide mimeticsEBI
TBA
 
The rational development of small molecule tachykinin NK3 receptor selective antagonists - the utilisation of a dipeptide chemical library in drug designEBI
TBA
 
Substituted 2,4-diaminoquinazolines and 2,4-diamino-8-alkylpurines as antagonists of the neurokinin-2 (NK2) receptorEBI
TBA
 
Alternative strategies towards the identification of chemical lead compounds by rational designEBI
TBA
 
Methionine replacements in biologically active peptidesEBI
TBA
 
Pharmacological profile and chemical synthesis of SR 48968, a non-peptide antagonist of the neurokinin A (NK2) receptorEBI
TBA
The discovery of (2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1- azabicyclo[2.2.2]-octan-3-amine as a novel, nonpeptide substance P antagonisst.EBI
Pfizer